<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">acpron</journal-id><journal-title-group><journal-title xml:lang="ru">Академия Практической Онкологии</journal-title><trans-title-group xml:lang="en"><trans-title>Academy for Practical Oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3033-9073</issn><issn pub-type="epub">3033-9421</issn><publisher><publisher-name>ООО "Издательский дом "МедИНК"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.63769/3033-9073-2026-1-2-75-80</article-id><article-id custom-type="elpub" pub-id-type="custom">acpron-20</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ СЛУЧАИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL CASES</subject></subj-group></article-categories><title-group><article-title>Синхронная лимфома Ходжкина у монозиготных (однояйцовых) близняшек: клинический случай стимуляции суперовуляции ингибиторами ароматазы и рекомбинантным фолликулостимулирующим гормоном</article-title><trans-title-group xml:lang="en"><trans-title>Synchronous hodgkin lymphoma in monozygotic twins: a case report of ovarian stimulation with aromatase inhibitors and recombinant follicle-stimulating hormone</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-5121-9609</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яговкина</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yagovkina</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Яговкина Ирина Александровна</p><p>Обнинск</p></bio><bio xml:lang="en"><p>Irina A. Yagovkina</p><p>Obninsk</p></bio><email xlink:type="simple">ir.yagovkina@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8464-1726</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Киселёва</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kiseleva</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Киселёва Марина Викторовна, д-р мед. наук, профессор</p><p>Обнинск</p></bio><bio xml:lang="en"><p>Marina V. Kiseleva, MD, Dr. Sci. (Medicine), Professor</p><p>Obninsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Медицинский радиологический научный центр им. А. Ф. Цыба – филиал Национального медицинского исследовательского центра радиологии</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A. F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>02</day><month>09</month><year>2026</year></pub-date><volume>1</volume><issue>2</issue><fpage>75</fpage><lpage>80</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Яговкина И.А., Киселёва М.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Яговкина И.А., Киселёва М.В.</copyright-holder><copyright-holder xml:lang="en">Yagovkina I.A., Kiseleva M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.apo-j.ru/jour/article/view/20">https://www.apo-j.ru/jour/article/view/20</self-uri><abstract><p>Лимфома Ходжкина (ЛХ) является одним из наиболее распространенных злокачественных заболеваний среди лиц молодого репродуктивного возраста. Высокие показатели долгосрочной выживаемости делают проблему сохранения фертильности крайне значимой для данной категории пациентов. Особую опасность в отношении гонадотоксичности представляют алкилирующие агенты (прокарбазин, циклофосфамид), входящие в состав стандартных схем полихимиотерапии (ПХТ). Однако случаи синхронного развития ЛХ у монозиготных близнецов с последующим проведением контролируемой стимуляции яичников в литературе описаны крайне редко.Представлено клиническое наблюдение успешного проведения стимуляции суперовуляции с применением ингибиторов ароматазы и рекомбинантного фолликулостимулирующего гормона (рФСГ) с последующей криоконсервацией ооцитов у 2 пациенток с синхронной классической ЛХ перед началом специфического противоопухолевого лечения.Пациентки – монозиготные близнецы 2000 года рождения с впервые диагностированной классической ЛХ: у первой установлена стадия IIА (международный прогностический индекс 0,4), у второй – стадия IVБ (международный прогностический индекс 1). Обеим пациенткам до начала ПХТ проведена программа стимуляции суперовуляции по протоколу с ингибиторами ароматазы и рФСГ с последующей трансвагинальной пункцией фолликулов и витрификацией полученных ооцитов. После завершения репродуктивных процедур пациентки получили ПХТ по схемам ABVD (6 циклов) и BEACOPP-14 (8 циклов) соответственно. Эффективность лечения оценивали по данным позитронно-эмиссионной томографии, совмещенной с компьютерной томографией.В ходе программ стимуляции удалось получить и криоконсервировать 7 зрелых ооцитов у первой пациентки и 5 – у второй. Процедуры переносились удовлетворительно; нежелательных явлений, потребовавших отмены или коррекции протокола, не зафиксировано. После завершения ПХТ у обеих пациенток достигнут полный метаболический ответ по данным позитронно-эмиссионной томографии, совмещенной с компьютерной томографией.Представленное наблюдение демонстрирует, что проведение контролируемой стимуляции яичников с использованием ингибиторов ароматазы и рФСГ с последующей криоконсервацией ооцитов является выполнимой и эффективной стратегией сохранения фертильности у пациенток с синхронной ЛХ, в том числе при распространенных стадиях заболевания, требующих интенсивных режимов ПХТ. Данный клинический случай подчеркивает необходимость раннего междисциплинарного взаимодействия онкологов и репродуктологов для своевременной реализации мероприятий по сохранению репродуктивной функции у молодых пациентов.</p></abstract><trans-abstract xml:lang="en"><p>Hodgkin lymphoma (HL) is one of the most common malignancies affecting young adults of reproductive age. Given the high long-term survival rates, fertility preservation has become a critical aspect of comprehensive patient care. Alkylating agents (procarbazine, cyclophosphamide), which are included in standard chemotherapy regimens, exhibit the highest gonadotoxic potential. However, cases of synchronous HL in monozygotic twins followed by controlled ovarian stimulation are extremely rare in the literature.Aim. To present a clinical case of successful controlled ovarian stimulation using Aromatase inhibitors and recombinant follicle-stimulating hormone (rFSH) with subsequent oocyte cryopreservation in two patients with synchronous classical HL prior to the initiation of antitumor therapy.The study included two monozygotic female twins born in 2000 with newly diagnosed classical HL. The first patient was diagnosed with stage IIA disease (international prognostic index 0.4), the second with stage IVB (international prognostic index 1). Both patients underwent controlled ovarian stimulation using a protocol with Aromatase inhibitors and rFSH, followed by transvaginal oocyte retrieval and vitrification of mature oocytes prior to chemotherapy. After completion of the fertility preservation procedures, the patients received polychemotherapy according to the ABVD regimen (6 cycles) and BEACOPP-14 (8 cycles), respectively. Treatment response was assessed by positron emission tomography / computed tomography.A total of 7 and 5 mature oocytes were successfully retrieved and cryopreserved in the first and second patient, respectively. Both procedures were well tolerated, with no adverse events requiring protocol modification  or discontinuation. Following completion of chemotherapy, both patients achieved complete metabolic response  on positron emission tomography / computed tomography.This case report demonstrates that controlled ovarian stimulation with Aromatase inhibitors and rFSH followed by oocyte cryopreservation is a feasible and effective fertility preservation strategy in patients with synchronous HL, including those with advanced-stage disease requiring intensive chemotherapy regimens. This observation underscores the critical importance of early multidisciplinary collaboration between oncologists and reproductive medicine specialists to ensure timely fertility preservation in young patients.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>лимфома Ходжкина</kwd><kwd>сохранение фертильности</kwd><kwd>криоконсервация ооцитов</kwd><kwd>стимуляция супер-овуляции</kwd><kwd>ингибиторы ароматазы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Hodgkin lymphoma</kwd><kwd>fertility preservation</kwd><kwd>oocyte cryopreservation</kwd><kwd>ovarian stimulation</kwd><kwd>aromatase inhibitors</kwd><kwd>oncofertility</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kahn J., Dabaja B., Wu S. et al. Classic Hodgkin lymphoma. Hematol Oncol 2024;42:e3239. DOI: 10.1002/hon.3239</mixed-citation><mixed-citation xml:lang="en">Kahn J., Dabaja B., Wu S. et al. Classic Hodgkin lymphoma. Hematol Oncol 2024;42:e3239. DOI: 10.1002/hon.3239</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Huang J., Pang W.S., Lok V. et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: A global data analysis. J Hematol Oncol 2022; 15:57. DOI: 10.1186/s13045-022-01281-9</mixed-citation><mixed-citation xml:lang="en">Huang J., Pang W.S., Lok V. et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: A global data analysis. J Hematol Oncol 2022; 15:57. DOI: 10.1186/s13045-022-01281-9</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Robert Koch Institute, Department of Epidemiology and Health Monitoring Available at: https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Morbus%20Hodgkin/morbus%20hodgkin_node.html</mixed-citation><mixed-citation xml:lang="en">Robert Koch Institute, Department of Epidemiology and Health Monitoring Available at: https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Morbus%20Hodgkin/morbus%20hodgkin_node.html</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Van Nimwegen F.A., Schaapveld M., Janus C.P. et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 2015;175(6):1007–17. DOI: 10.1001/jamainternmed.2015.1180</mixed-citation><mixed-citation xml:lang="en">Van Nimwegen F.A., Schaapveld M., Janus C.P. et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 2015;175(6):1007–17.  DOI: 10.1001/jamainternmed.2015.1180</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">De Vries S., Schaapveld M., Janus C.P.M. et al. Long-term cause-specific mortality in Hodgkin lymphoma patients. J Natl Cancer Inst 2021;113:760–9. DOI: 10.1093/jnci/djaa194</mixed-citation><mixed-citation xml:lang="en">De Vries S., Schaapveld M., Janus C.P.M. et al. Long-term cause-specific mortality in Hodgkin lymphoma patients. J Natl Cancer Inst 2021;113:760–9. DOI: 10.1093/jnci/djaa194</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson A.C., Mays D., Rehberg K. et al. Knowledge and beliefs about oncofertility and associations with quality of life among adolescent and young adult survivors of pediatric cancer. J Adolesc Young Adult Oncol 2018;7:424–9. DOI: 10.1089/jayao.2018.0014</mixed-citation><mixed-citation xml:lang="en">Johnson A.C., Mays D., Rehberg K. et al. Knowledge and beliefs about oncofertility and associations with quality of life among adolescent and young adult survivors of pediatric cancer. J Adolesc Young Adult Oncol 2018;7:424–9. DOI: 10.1089/jayao.2018.0014</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Benedict C., Thom B., Friedman D.N. et al. Fertility information needs and concerns post-treatment contribute to lowered quality of life among young adult female cancer survivors. Support Care Cancer 2018;26:2209–15. DOI: 10.1007/s00520-017-4006-z</mixed-citation><mixed-citation xml:lang="en">Benedict C., Thom B., Friedman D.N. et al. Fertility information needs and concerns post-treatment contribute to lowered quality  of life among young adult female cancer survivors. Support Care Cancer 2018;26:2209–15. DOI: 10.1007/s00520-017-4006-z</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kiseleva M.V., Lunkova M.N. Preservation of fertility in patients with breast cancer. Literature review. Practice Oriented Science UAE-RUSSIA-INDIA. UAE 2023:149–63.</mixed-citation><mixed-citation xml:lang="en">Kiseleva M.V., Lunkova M.N. Preservation of fertility in patients with breast cancer. Literature review. Practice Oriented Science UAE-RUSSIA-INDIA. UAE 2023:149–63.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kiserud C.E., Fosså A., Bjøro T. et al. Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer 2009;100:455–63. DOI: 10.1038/sj.bjc.6604892</mixed-citation><mixed-citation xml:lang="en">Kiserud C.E., Fosså A., Bjøro T. et al. Gonadal function in male patients after treatment for malignant lymphomas, with emphasis  on chemotherapy. Br J Cancer 2009;100:455–63.  DOI: 10.1038/sj.bjc.6604892</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kulkarni S.S., Sastry P.S., Saikia T.K. et al. Gonadal function following ABVD therapy for Hodgkin’s disease. Am J Clin Oncol 1997;20:354–7. DOI: 10.1097/00000421-199708000-00006</mixed-citation><mixed-citation xml:lang="en">Kulkarni S.S., Sastry P.S., Saikia T.K. et al. Gonadal function following ABVD therapy for Hodgkin’s disease.  Am J Clin Oncol 1997;20:354–7.  DOI: 10.1097/00000421-199708000-00006</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Oktem O., Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007;110:2222–9. DOI: 10.1002/cncr.23071</mixed-citation><mixed-citation xml:lang="en">Oktem O., Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007;110:2222–9. DOI: 10.1002/cncr.23071</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Sonigo C., Beau I., Binart N. et al. The impact of chemotherapy on the ovaries: molecular aspects and the prevention of ovarian damage. Int J Mol Sci 2019;20:5342. DOI: 10.3390/ijms20215342</mixed-citation><mixed-citation xml:lang="en">Sonigo C., Beau I., Binart N. et al. The impact of chemotherapy  on the ovaries: molecular aspects and the prevention  of ovarian damage. Int J Mol Sci 2019;20:5342.  DOI: 10.3390/ijms20215342</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Spears N., Lopes F., Stefansdottir A. et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update 2019;25:673–93. DOI: 10.1093/humupd/dmz027</mixed-citation><mixed-citation xml:lang="en">Spears N., Lopes F., Stefansdottir A. et al. Ovarian damage from chemotherapy and current approaches to its protection.  Hum Reprod Update 2019;25:673–93.  DOI: 10.1093/humupd/dmz027</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Локшин В.Н., Карибаева Ш.К., Исенова С.Ш. и др. Сохранение онкофертильности у онкологических больных. В кн.: Практическая репродуктология. Казахстан, Алматы, 2023. 386 с.</mixed-citation><mixed-citation xml:lang="en">Lokshin V.N., Karibaeva Sh.K., Isenova S.Sh. et al. Preservation  of oncofertility in cancer patients. In: Practical Reproductology. Kazakhstan, Almaty, 2023. 386 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Репродуктивное здоровье онкологических больных. Онкология: учебник. Под ред. А.Д. Каприна. М.: Молодая гвардия, 2025. 568 с. С. 306–311.</mixed-citation><mixed-citation xml:lang="en">Reproductive health of cancer patients. Oncology: textbook.  Ed. by A.D. Kaprin. Moscow: Molodaya Gvardiya, 2025. 568 p.  Рр. 306–311. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Vidal A., Nordhoff V., Suerdieck M. et al. Development of medical freezing measures in women during the last decade from 2014 to 2023: registry data of the tri-national network FertiPROTEKT. Arch Gynecol Obstet 2026;313:36. DOI: 10.1007/s00404-025-08253-7</mixed-citation><mixed-citation xml:lang="en">Vidal A., Nordhoff V., Suerdieck M. et al. Development of medical freezing measures in women during the last decade from 2014 to 2023: registry data of the tri-national network FertiPROTEKT. Arch Gynecol Obstet 2026;313:36. DOI: 10.1007/s00404-025-08253-7</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
